Results 11 to 20 of about 26,368 (251)

Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel [PDF]

Nature Communications
Paclitaxel and nab-paclitaxel differ in therapeutic efficacy and modulation of the tumor immune microenvironment, yet the molecular basis remains poorly defined.
Yuqi Xing, Ruiqi Zhong, Qianchen Li, Xinwei Duan, Moyang Xu, Miao Yu, Chenying Liu, Junming He, Yi Sun, Yunling Wang, Xiaojing Guo, Yunfei Xu, Hongnan Mo, Fei Ma, Hongquan Zhang, Jun Zhan   +15 more
doaj   +2 more sources

Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma [PDF]

Pancreatology, 2013
BACKGROUND: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. MATERIALS AND
Cho, May, Gao, Feng, Peddi, Parvin F, Wang, Jian, Wang-Gillam, Andrea   +4 more
core   +4 more sources

Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks [PDF]

Scientific Reports
Nab-paclitaxel (albumin-bound paclitaxel) and traditional paclitaxel are both used in pancreatic cancer treatment, but their adverse event (AE) profiles may differ due to formulation differences.
Nan Qin, Zhongliu Bian, Jingtao Chen
doaj   +2 more sources

Influence of Consecutive Nab-Paclitaxel Chemotherapy Cycles on Gut Microbiota and Pharmacokinetic Behavior [PDF]

Technology in Cancer Research & Treatment
Introduction Nab-paclitaxel is a mainstay of treatment for a broad spectrum of cancers and is typically administered over multiple cycles. The anti-mitotic effects of nab-paclitaxel are well-established.
Xinyue Zhang MS, Weiwei Xie MS, Yuqian Zhang MS, Ye Yuan MS, Jingpu Xu MS, Jian Liu MS   +5 more
doaj   +2 more sources

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial [PDF]

Nature Communications
In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel.
Chuntao Gao, Yanqiao Zhang, Xiujuan Qu, Xingyun Chen, Jingdong Zhang, Heshui Wu, Meili Sun, Yong Zha, Junbin Wang, Yusheng Wang, Zhihua Li, Jinghua Gao, Rongbo Lin, Aimin Zang, Huiqing Zhang, Xianglin Yuan, Chengyou Du, Jun Zhao, Yongsheng Yang, Xuetao Shi, Wei Cheng, Bangmao Wang, Shikai Wu, Tiansuo Zhao, Jian Wang, Song Gao, Xiuchao Wang, Weidong Ma, Rui Liu, Yehui Shi, Yanping Liu, Yijiao Xie, Miao Niu, Fuchen Zhao, Jun Yu, Jihui Hao   +35 more
doaj   +2 more sources

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports

Case Reports in Oncology, 2020
A standard chemotherapy regimen for advanced thymic carcinoma has not yet been established. We treated 2 cases of thymic carcinoma with carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel, and nab-paclitaxel maintenance therapy.
Tomoyuki Araya, Toshiyuki Kita, Hiroki Matsuoka, Tamami Sakai, Hideharu Kimura, Kazuo Kasahara   +5 more
doaj   +3 more sources

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Frontiers in Oncology, 2022
Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently
Zhichao Tian, Weitao Yao
doaj   +1 more source

Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review

Frontiers in Oncology, 2021
Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel).
Suna Ye, Suna Ye, Qiqi Fang, Jinyu Yao, Jianqiang Xing, Shibo Tang, Shibo Tang, Jacey Hongjie Ma, Jacey Hongjie Ma   +8 more
doaj   +1 more source

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety

BMC Cancer, 2022
Background Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with a poor prognosis. Approximately 20% of TNBC has been found to express programmed death ligand 1 (PD-L1), making it a potential therapeutic target.
K. Sharmni Vishnu, Thin Thin Win, Saint Nway Aye, Arun Kumar Basavaraj   +3 more
doaj   +1 more source

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2023
Background: Most patients with small-cell lung cancer (SCLC) experience disease progression after first-line chemotherapy. Notably, nab-paclitaxel monotherapy has antitumor activity in relapsed SCLC.
Rui Wan, Yanrong Guo, Xuezhi Hao, Zhijie Wang, Jianchun Duan, Jie Wang   +5 more
doaj   +1 more source